TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number:

C0989.70031US00

In re Application of:

Application No.

Confirmation No.

Filed:

For:

February 14, 2001
METHODS AND APPARATUSES FOR CHARACTERIZATION OF SINGLE POLYMERS

omics, Inc., of 100% percent of interest owned in eating the provided below, the terminal part of ication which would extend in §154 to 8157 The owner*, U.S. Genomics, Inc., of 100% percent of interest owned in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173, as presently shortened by any terminal disclaimer, of Patent Application No. 09/875,779 ("the patent") if such patent issues. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of the patent if such patent issues, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, never issues, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false-statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United states Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

> Signature Date

id Bernstein on behalf of U.S. Genomics, Inc.

Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP §324.



CERTIFICATE UNDER 37 CFR 3.73(b)

Patent Owner:

U.S. Genomics, Inc.

Patent Application No.:

09/875,779

Filed:

June 6, 2001

Entitled:

PRECEIVED TOO RECEIVED TOO RECEIVED TOO METHODS AND APPARATUS FOR CHARACTERIZATION OF SINGLE

POLYMERS

U.S. Genomics, Inc., certifies that it is the assignee of the entire right, title, and interest in the patent identified above by virtue of an assignment from the inventors recorded in the Patent and Trademark Office at Reel 012244, Frame 0876.

The undersigned is empowered to sign this certificate on behalf of the assignee.

October 22, 2003

Date

Name: David B. Bernsfein

Title: Corporate Secretary, General Gunsal

U.S. Genomics, Inc.